Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
HPHA
vs
DAX Index
HPHA
Over the past 12 months, HPHA has underperformed DAX Index, delivering a return of -28% compared to DAX Index's +7% growth.
Stocks Performance
HPHA vs DAX Index
Performance Gap
HPHA vs DAX Index
Create a free account · No card needed
Performance By Year
HPHA vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Heidelberg Pharma AG
Glance View
Heidelberg Pharma is a German biotechnology company focused on cancer drugs. It does not sell a consumer product; instead, it develops antibody-drug conjugates, or ADCs, that attach a toxic payload to an antibody so the medicine can target cancer cells more precisely. Its best-known work is based on its ATAC technology, which uses a toxin called amanitin. The company makes money in two main ways: by advancing its own drug candidates and by working with pharmaceutical partners on research and licensing deals. Partners pay for access to its technology, and the company can also earn milestone payments and royalties if those drug programs succeed. In that model, Heidelberg Pharma acts as a technology owner and drug developer rather than a large-scale drug manufacturer. For beginners, the key point is that Heidelberg Pharma sits in the early-to-mid stage of the cancer drug value chain. It sells scientific know-how, drug candidates, and platform access to other drug companies, while aiming to turn its own research into future medicines for patients with hard-to-treat cancers.
Create a free account · No card needed